Clinical Trial: Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus
Brief Summary: This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.
Detailed Summary: No sampling as no subjects are enrolled
Sponsor: Pfizer
Current Primary Outcome: Incidence of IPD in the NCKP healthcare system in children 6 weeks through 5 years of age (prior to the sixth birthday) during each of the 5 years following introduction of Prevnar 13. [ Time Frame: 5 years ]
Original Primary Outcome: NA - no intervention
Current Secondary Outcome:
Original Secondary Outcome: NA - no intervention
Information By: Pfizer
Dates:
Date Received: May 20, 2010
Date Started: July 2010
Date Completion:
Last Updated: June 9, 2015
Last Verified: June 2015